Myron D Ginsberg, Yuko Y Palesch, Michael D Hill, Renee H Martin, Claudia S Moy, William G Barsan, Bonnie D Waldman, Diego Tamariz, Karla J Ryckborst
BACKGROUND: In animal models of ischaemic stroke, 25% albumin reduced brain infarction and improved neurobehavioural outcome. In a pilot clinical trial, albumin doses as high as 2 g/kg were safely tolerated. We aimed to assess whether albumin given within 5 h of the onset of acute ischaemic stroke increased the proportion of patients with a favourable outcome. METHODS: We did a randomised, double-blind, parallel-group, phase 3, placebo-controlled trial between Feb 27, 2009, and Sept 10, 2012, at 69 sites in the USA, 13 sites in Canada, two sites in Finland, and five sites in Israel...
November 2013: Lancet Neurology